Abstract
Skin colour is known to confound readouts from optical devices that make measurements through the skin, which can adversely impact the care of patients with darker skin. Photoacoustic imaging (PAI) is making its way from the laboratory to the clinic, however, combining optics and ultrasound for deep tissue imaging leads to a complex relationship between photoacoustic-derived imaging biomarkers and skin melanin concentration. Furthermore, no generalisable correction of the confounding effects of skin colour in PAI has been demonstrated. We sought to overcome this limitation by recruiting a healthy volunteer cohort with the most diverse range of skin tones ever assembled in the field, with participants from Fitzpatrick types I to VI and with vitiligo. From this comprehensive dataset, we identified and characterised two physical mechanisms responsible for skin colour-dependent degradation in both image quality and biomarker quantification. Accompanied by detailed theoretical modelling, we demonstrated that strong light absorption by melanin leads to spectral colouring, which dominates in individuals with low skin melanin pigmentation. We further identified the backscattering of ultrasound waves generated in the skin as a major source of image artefacts for individuals with high skin melanin pigmentation. With this improved understanding of the physical basis, we were able to develop a fast and practicable correction method for spectral colouring and adapted a plane-wave ultrasound reconstruction algorithm to reveal the ultrasound scatterer distribution encoded in the photoacoustic timeseries. Our findings highlight the need for more advanced image reconstruction methods to enable equitable clinical application of PAI.
One Sentence Summary Photoacoustic imaging is proven to suffer from measurement inaccuracies in people with darker skin, which could adversely impact patient care if not appropriately corrected.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Cancer Research UK C9545/A29580 Cancer Research UK C64667/A27958 Engineering and Physical Sciences Research Council UK EP/X037770/1 National Institute of Health Research UK NIHR203312 Cancer Research UK EDDAMC-2023/100003 Deutsche Forschungsgemeinschaft Walter Benjamin Stipendium
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The East of England Cambridge South Research Committee of the National Heath Service gave ethical approval for this study
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data associated with this manuscript will be made available on the University of Cambridge data repository upon publication in a peer-reviewed journal. Before that time, data produced are available upon reasonable request to the authors.
